LLS, Forma Join To Develop Anti-cancer Therapies
LLS has committed substantial, multi-year funding to support this collaboration, which is an expansion of partnership between both the companies in July 2009, as part of its Therapy
Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33, a clinical-stage anti-IL-33 monoclonal antibody, in a deal that includes potential development and sales milestone payments of up to around $560m.
Battelle, an independent research and development organisation, has agreed to provide comprehensive pre-clinical research and development services, including infectious disease model development and product safety and efficacy evaluations